{"protocolSection":{"identificationModule":{"nctId":"NCT03982199","orgStudyIdInfo":{"id":"CR108634"},"secondaryIdInfos":[{"id":"VAC18193RSV2001","type":"OTHER","domain":"Janssen Vaccines & Prevention B.V."}],"organization":{"fullName":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"},"briefTitle":"A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older","officialTitle":"A Randomized, Double-blind, Placebo-controlled Phase 2b Study to Assess the Efficacy, Immunogenicity and Safety of an Ad26.RSV.preF-based Regimen in the Prevention of RT PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older","acronym":"CYPRESS"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"TERMINATED","whyStopped":"The study was terminated early by the sponsor due to strategic reprioritization reasons.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-08-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-06-06","type":"ACTUAL"},"completionDateStruct":{"date":"2023-05-26","type":"ACTUAL"},"studyFirstSubmitDate":"2019-06-10","studyFirstSubmitQcDate":"2019-06-10","studyFirstPostDateStruct":{"date":"2019-06-11","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-06-06","resultsFirstSubmitQcDate":"2023-07-21","resultsFirstPostDateStruct":{"date":"2023-07-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-22","lastUpdatePostDateStruct":{"date":"2025-05-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to demonstrate the efficacy of active study vaccine in the prevention of reverse transcriptase polymerase chain reaction (RT-PCR) confirmed respiratory syncytial virus (RSV)-mediated lower respiratory tract disease (LRTD), when compared to placebo."},"conditionsModule":{"conditions":["Respiratory Syncytial Viruses","Respiratory Tract Diseases"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":5815,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group 1: RSV Vaccine","type":"EXPERIMENTAL","description":"Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1. Participants will then be divided into revaccination subcohorts: 1A, 1B, and 1C to receive revaccination with Ad26.RSV.preF based vaccine at 1 year, 2 years, and 3 years respectively after the first vaccination.","interventionNames":["Biological: RSV Vaccine"]},{"label":"Group 2: Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive a single IM injection of placebo control on Day 1. Participants will then be divided into revaccination subcohorts 2A, 2B, and 2C, and will first receive Ad26.RSV.preF based vaccine at years 1, 2, and 3. In subcohorts 2A and 2B, participants will receive a revaccination one year later with either Ad26.RSV.preF based vaccine, study vaccine A or study vaccine B.","interventionNames":["Biological: RSV Vaccine","Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"RSV Vaccine","description":"Participants will receive a single IM injection of an Ad26-based RSV vaccine at a single dose level on Day 1 and revaccination after either 1 year, 2 years, or 3 years.","armGroupLabels":["Group 1: RSV Vaccine","Group 2: Placebo"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Participants will receive a single IM injection of placebo control on Day 1.","armGroupLabels":["Group 2: Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD)","description":"Number of participants with first occurrence of RT-PCR-confirmed RSV mediated LRTD according to case definition-1, 2 and 3 were reported. Case definition 1 was defined as having a new onset or worsening in 3 or more symptoms of lower respiratory tract infection (LRTI) ; Case definition 2 was defined as having a new onset or worsening in greater than or equal to (\\>=) 2 symptoms of LRTI; and Case definition 3 was defined as having a new onset or worsening in \\>=2 OR \\>=1 symptoms of LRTI with \\>=1 systemic symptoms. Systemic symptoms (fatigue/malaise and fever/feverishness) and symptoms of LRTI (cough, shortness of breath, sputum production, wheezing and tachypnea) were collected via the RiiQ. RiiQ symptom scale was a 13-items questionnaire rated on a 4-point scale. Each symptom was rated on a scale of 0 to 3 where 0=None, 1=Mild, 2=Moderate, and 3=Severe. Higher scores indicated greater severity. The total LRTD symptom score was calculated as the mean of the LRTD symptom scores.","timeFrame":"From screening (Day 1) up to 9 months"}],"secondaryOutcomes":[{"measure":"Main Cohorts: Number of Participants With Any RT-PCR-confirmed RSV Disease","description":"Number of participants with any RT-PCR-confirmed RSV disease were reported. The analysis was based on poisson regression model.","timeFrame":"From screening (Day 1) up to 9 months"},{"measure":"Main Cohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers","description":"RSV A2 strain neutralizing antibody titers of the vaccine-induced immune response was assessed through virus neutralization assay.","timeFrame":"Days 15, 85, 169, 365"},{"measure":"Revaccination Subcohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers","description":"RSV A2 strain neutralizing antibody titers of the vaccine-induced immune response was assessed through virus neutralization assay.","timeFrame":"Days 15, 365, 379, 393, 449, 730, 737, 744, 758"},{"measure":"Revaccination Subcohorts: Geometric Mean Titers (GMTs) of Prefusion F-protein (Pre-F) A Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)","description":"GMTs of preF-A antibodies after the administration of Ad26.RSV.preF-based vaccine as assessed by ELISA were reported.","timeFrame":"Day 15: Arms 3 to 7,13 and 14; Days 365, 379, 393, 449, 533: Arms 3 to 7; Day 730: Arms 4 to 7; Days 737, 744, 758: Arms 5 to 7; Day 1095, 1109: Arms 13 and 14"},{"measure":"Revaccination Subcohort 2A: T-cell Interferon (IFN) Gamma Responses to RSV F Protein Peptides Analyzed by Enzyme-linked Immunospot Assay (ELISpot)","description":"T-cell IFN gamma responses to RSV F protein specific peptides as measured by ELISpot assay were reported. RSV F protein specific T-cell IFN gamma ELISpot responses were measured as counts of spot forming cells per million peripheral blood mononuclear cells (SFC/10\\^6 PBMCs).","timeFrame":"Days 730, 744, 758"},{"measure":"Main Cohorts: T-cell Interferon (IFN) Gamma Responses to RSV F Protein Peptides Analyzed by Enzyme-linked Immunospot Assay (ELISpot)","description":"T-cell IFN gamma responses to RSV F protein specific peptides as measured by ELISpot assay were reported. RSV F protein specific T-cell IFN gamma ELISpot responses were measured as counts of spot forming cells per million peripheral blood mononuclear cells (SFC/10\\^6 PBMCs).","timeFrame":"Days 15, 85, 169, 365, 533"},{"measure":"Main Cohorts: Number of Participants With Solicited Local Adverse Events (AEs) up to 7 Days After First Vaccination","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Solicited local AEs were precisely defined events that participants were specifically asked about and which were noted by participants in the diary. Solicited local AEs included erythema, swelling/induration, and pain/tenderness. Per protocol, all solicited local AEs were considered as related to intervention.","timeFrame":"Up to Day 8 (7 days after first vaccination on Day 1)"},{"measure":"Main Cohorts: Number of Participants With Solicited Systemic AEs up to 7 Days After First Vaccination","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Solicited systemic AEs included fatigue, headache, myalgia, arthralgia, and fever (defined as an endogenous elevation of body temperature \\>=38.0°C, as recorded in at least one measurement).","timeFrame":"Up to Day 8 (7 days after first vaccination on Day 1)"},{"measure":"Main Cohorts: Number of Participants With Unsolicited AEs up to 28 Days After First Vaccination","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Unsolicited adverse events included all adverse events for which the participant is not specifically questioned in the participant diary.","timeFrame":"Up to Day 29 (28 days after first vaccination on Day 1)"},{"measure":"Revaccination Subcohorts: Number of Participants With Solicited Local AEs 7 Days After Re-vaccination up to 1, 2 and 3 Years","description":"Number of participants with solicited local AEs 7 days after re-vaccination at 1, 2 and 3 years were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Solicited local AEs were precisely defined events that participants were specifically asked about and which were noted by participants in the diary. Solicited local AEs included erythema, swelling/induration, and pain/tenderness. Per protocol, all solicited local AEs were considered as related to intervention.","timeFrame":"Arms 3,4: 7 days after revacc at 1 year (up to Day 372); Arm 5,6,7,8,9: 7 days after revacc at 2 years (up to Day 737); Arms 10,11,12,13,14: 7 days after revacc at 3 year (up to Day 1102)"},{"measure":"Revaccination Subcohorts: Number of Participants With Solicited Systemic AEs 7 Days After Re-vaccination up to 1, 2 and 3 Years","description":"Number of participants with solicited systemic AEs 7 days after re-vaccination up to 1, 2 and 3 years were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Solicited systemic AEs included fatigue, headache, myalgia, arthralgia, and fever (defined as an endogenous elevation of body temperature \\>=38.0°C, as recorded in at least one measurement).","timeFrame":"Arms 3,4: 7 days after revacc at 1 year (up to Day 372); Arm 5,6,7,8,9: 7 days after revacc at 2 years (up to Day 737); Arms 10,11,12,13,14: 7 days after revacc at 3 year (up to Day 1102)"},{"measure":"Revaccination Subcohorts: Number of Participants With Unsolicited AEs 28 Days After Re-vaccination up to 1, 2 and 3 Years","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Unsolicited adverse events included all adverse events for which the participant is not specifically questioned in the participant diary.","timeFrame":"Arms 3,4: 28 days after revacc at 1 year (up to Day 393); Arms 5,6,7,8,9: 28 days after revacc at 2 years (up to Day 758); Arms 10,11,12,13,14: 28 days after revaccination at 3 year (up to Day 1123)"},{"measure":"Revaccination Subcohorts: Number of Participants With Adverse Events of Special Interests (AESI)","description":"Number of participants with AESIs were reported. An AE was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Thrombosis with thrombocytopenia syndrome (TTS) was considered as an AESI.","timeFrame":"Arms 3,4: 6 months after revacc at 1 year (up to Day 547); Arm 5,6,7,8,9: 6 months after revacc at 2 years (up to Day 912); Arms 10,11,12,13,14: 6 months after revacc at 3 year (up to Day 1277)"},{"measure":"Main Cohorts:Number of Participants With Serious Adverse Events (SAEs)","description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. For participants who were not revaccinated only SAEs associated with ARIs and complications related to ARIs that classify as SAEs, SAEs classified as related, SAEs resulting in death, and (S)AEs resulting in study discontinuation or from procedures and non-investigational (concomitant) Janssen products were collected.","timeFrame":"From Day 1 up to Day 1095"},{"measure":"Revaccination Subcohorts: Number of Participants With Serious Adverse Events (SAEs)","description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","timeFrame":"Arms 3,4: 6 months after revacc at 1 year (up to Day 547); Arm 5,6,7,8,9: 6 months after revacc at 2 years (up to Day 912); Arms 10,11,12,13,14: 6 months after revacc at 3 year (up to Day 1277)"},{"measure":"Main Cohorts: Geometric Mean Titers (GMTs) of Prefusion F-protein (Pre-F) A Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)","description":"GMTs of preF-A antibodies after the administration of Ad26.RSV.preF-based vaccine as assessed by ELISA were reported.","timeFrame":"Days 15, 85, 169, 365, 533"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant must have a body mass index (BMI) less than (\\<)40 kilogram per meter square (kg/m\\^2)\n* Before randomization, a woman must be: postmenopausal (postmenopausal state is defined as no menses for 12 months without an alternative medical cause); and not intending to conceive by any methods\n* Participant must be either in good or stable health. Participants may have mild to moderate underlying illnesses such as chronic cardiac diseases and chronic lung disease (asthma and chronic obstructive pulmonary disease \\[COPD\\]), congestive heart failure (CHF), hypertension, type 2 diabetes mellitus, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms and signs are stable and medically controlled in the judgment of the investigator. Participants will be included on the basis of physical examination, medical history, and vital signs performed between informed consent form (ICF) signature and vaccination on Day 1\n* From the time of vaccination through 3 months after vaccination, participant agrees not to donate blood\n* Participant must be able to read, understand, and complete questionnaires in the eDiary (or a paper safety diary, if designated by the sponsor)\n* Participant must be willing to provide verifiable identification, have means to be contacted and to contact the investigator during the study\n\nExclusion Criteria:\n\n* Participant has an acute illness (including acute respiratory illnesses) or body temperature greater than or equal to (\\>=)38.0 degree Celsius (ºC) within 24 hours prior to administration of study vaccine. In such a situation, enrollment at a later date is permitted\n* Participant has a severe or potentially life-threatening chronic disorder such as severe chronic cardiac diseases and severe chronic lung disease (asthma and COPD), advanced CHF, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, Alzheimer's disease, or has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example: compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments\n* Participant has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)\n* Per medical history, participant has chronic active hepatitis B or hepatitis C infection\n* Per medical history, participant has human immunodeficiency virus (HIV) type 1 or type 2 infection\n* Participant has a known allergy, or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine components (including any of the constituents of the study vaccine)","healthyVolunteers":true,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Janssen Vaccines & Prevention B.V. Clinical Trial","affiliation":"Janssen Vaccines & Prevention B.V.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Optimal Research","city":"Huntsville","state":"Alabama","zip":"35802","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"Synexus Clinical Research US Inc","city":"Chandler","state":"Arizona","zip":"85224","country":"United States","geoPoint":{"lat":33.30616,"lon":-111.84125}},{"facility":"Synexus Clinical Research US Inc","city":"Phoenix","state":"Arizona","zip":"85018","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Central Phoenix Medical Clinic","city":"Phoenix","state":"Arizona","zip":"85020","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Anaheim Clinical Trials, LLC","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Paradigm Clinical Research Centers, Inc.","city":"Redding","state":"California","zip":"96001","country":"United States","geoPoint":{"lat":40.58654,"lon":-122.39168}},{"facility":"Benchmark Research","city":"Sacramento","state":"California","zip":"95684","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"Optimal Research","city":"San Diego","state":"California","zip":"92108","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Synexus Clinical Research US Inc","city":"Aurora","state":"Colorado","zip":"80014","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Lynn Institute","city":"Colorado Springs","state":"Colorado","zip":"80920","country":"United States","geoPoint":{"lat":38.83388,"lon":-104.82136}},{"facility":"Optimal Research","city":"Melbourne","state":"Florida","zip":"32934","country":"United States","geoPoint":{"lat":28.08363,"lon":-80.60811}},{"facility":"Advanced Clinical Research","city":"Boise","state":"Idaho","zip":"83642","country":"United States","geoPoint":{"lat":43.6135,"lon":-116.20345}},{"facility":"Optimal Research","city":"Peoria","state":"Illinois","zip":"61614","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"Synexus Clinical Research US Inc","city":"Evansville","state":"Indiana","zip":"47714","country":"United States","geoPoint":{"lat":37.97476,"lon":-87.55585}},{"facility":"The Iowa Clinic","city":"West Des Moines","state":"Iowa","zip":"50266","country":"United States","geoPoint":{"lat":41.57721,"lon":-93.71133}},{"facility":"Hutchinson Clinic","city":"Hutchinson","state":"Kansas","zip":"67502","country":"United States","geoPoint":{"lat":38.06084,"lon":-97.92977}},{"facility":"Johnson County Clin-Trials","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"Heartland Research Associates, LLC","city":"Newton","state":"Kansas","zip":"67114","country":"United States","geoPoint":{"lat":38.04668,"lon":-97.34504}},{"facility":"Heartland Research Associates, LLC","city":"Wichita","state":"Kansas","zip":"67205","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Optimal Research","city":"Rockville","state":"Maryland","zip":"20850","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"Synexus Clinical Research US Inc","city":"Richfield","state":"Minnesota","zip":"55432","country":"United States","geoPoint":{"lat":44.8833,"lon":-93.283}},{"facility":"The Center For Pharmaceutical Research","city":"Kansas City","state":"Missouri","zip":"64114","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Sundance Clinical Research","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Synexus Clinical Research US Inc","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Synexus Clinical Research US Inc","city":"Elkhorn","state":"Nebraska","zip":"68022","country":"United States","geoPoint":{"lat":41.345,"lon":-96.256}},{"facility":"Synexus Clinical Research US Inc","city":"Omaha","state":"Nebraska","zip":"68144","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"United Medical Associates","city":"Binghamton","state":"New York","zip":"13901","country":"United States","geoPoint":{"lat":42.09869,"lon":-75.91797}},{"facility":"Regional Clinical Research, Inc.","city":"Endwell","state":"New York","zip":"13760","country":"United States","geoPoint":{"lat":42.11285,"lon":-76.02103}},{"facility":"University of Rochester / Rochester General Hospital","city":"Rochester","state":"New York","zip":"14621","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Synexus Clinical Research US Inc","city":"Akron","state":"Ohio","zip":"44311","country":"United States","geoPoint":{"lat":41.08144,"lon":-81.51901}},{"facility":"Synexus Clinical Research US Inc","city":"Cincinnati","state":"Ohio","zip":"45236","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Rapid Medical Research","city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Lynn Health Science Institute","city":"Oklahoma City","state":"Oklahoma","zip":"73112","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Omega Medical Research","city":"Warwick","state":"Rhode Island","zip":"02886","country":"United States","geoPoint":{"lat":41.7001,"lon":-71.41617}},{"facility":"Coastal Carolina Research Center","city":"Mt. Pleasant","state":"South Carolina","zip":"29464","country":"United States","geoPoint":{"lat":32.79407,"lon":-79.86259}},{"facility":"Optimal Research","city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Ventavia Research Group, LLC","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Synexus Clinical Research US Inc","city":"Murray","state":"Utah","zip":"84123","country":"United States","geoPoint":{"lat":40.66689,"lon":-111.88799}},{"facility":"Advanced Clinical Research","city":"Salt Lake City","state":"Utah","zip":"84123","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Advanced Clinical Research","city":"West Jordan","state":"Utah","zip":"84088","country":"United States","geoPoint":{"lat":40.60967,"lon":-111.9391}}]},"referencesModule":{"references":[{"pmid":"38801826","type":"DERIVED","citation":"Falsey AR, Hosman T, Bastian AR, Vandenberghe S, Chan EKH, Douoguih M, Heijnen E, Comeaux CA, Callendret B; CYPRESS investigators. Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study. Lancet Infect Dis. 2024 Sep;24(9):1015-1024. doi: 10.1016/S1473-3099(24)00226-3. Epub 2024 May 24."},{"pmid":"36791161","type":"DERIVED","citation":"Falsey AR, Williams K, Gymnopoulou E, Bart S, Ervin J, Bastian AR, Menten J, De Paepe E, Vandenberghe S, Chan EKH, Sadoff J, Douoguih M, Callendret B, Comeaux CA, Heijnen E; CYPRESS Investigators. Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults. N Engl J Med. 2023 Feb 16;388(7):609-620. doi: 10.1056/NEJMoa2207566."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency.\n\nAs noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu","url":"https://www.janssen.com/clinical-trials/transparency"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants in the main cohort who did not enter the re-vaccination subcohorts continued in the main cohort up to Day 1095. Hence, the assessments for both main cohorts and re-vaccination subcohorts were conducted in parallel until Day 1095 (end of main cohort).","groups":[{"id":"FG000","title":"Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture)","description":"Adult participants aged greater than or equal to (\\>=) 65 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) (protein mixture) on Day 1. Participants were divided into revaccination subcohorts: 1A, 1B, and 1C. Participants further received revaccination with the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 1A), 2 (Subcohort 1B), and 3 (Subcohort 1C) years, respectively after the first vaccination on Day 1. Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."},{"id":"FG001","title":"Arm 2: Main Cohort: Group 2: Placebo","description":"Adult participants aged \\>=65 years received a single IM injection of placebo on Day 1. Participants were divided into revaccination subcohorts: 2A, 2B, and 2C. Participants further received revaccination with Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 2A), 2 (Subcohort 2B), and 3 (Subcohort 2C) years, respectively after the first vaccination on Day 1. Participants in subcohorts 2A and 2B were additionally re-randomised in three groups at Year 3 and Year 4, respectively, to receive either Ad26.RSV.preF 1\\*10\\^11 vp alone, RSV preF protein 150 mcg alone or the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture). Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."},{"id":"FG002","title":"Arm 3: Revaccination (ReVacc) Subcohort 1A: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort 1A and received IM injection of the protein mixture at the same dose level on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"FG003","title":"Arm 4: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein Mixture","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"FG004","title":"Arm 5: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.PreF Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 in the revaccination subcohort further received Ad26.RSV.preF 1\\*10\\^11 vp alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"FG005","title":"Arm 6: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein (protein mixture) on Day 365 in the revaccination subcohort further received RSV preF protein 150 mcg alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"FG006","title":"Arm 7: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 and 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"FG007","title":"Arm 8: ReVacc Subcohort 1B: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"FG008","title":"Arm 9: ReVacc Subcohort 2B:Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"FG009","title":"Arm 10: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.preF","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by Ad26.RSV.preF 1\\*10\\^11 vp alone on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"FG010","title":"Arm 11: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by RSV preF protein 150 mcg alone on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"FG011","title":"Arm 12: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Days 730 and Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"FG012","title":"Arm 13: ReVacc Subcohort 1C: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"FG013","title":"Arm 14: ReVacc Subcohort 2C: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1095. Participants were then followed up for safety assessments till Day 1460."}],"periods":[{"title":"Main Cohorts (Day 1 up to Day 1095)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"2909"},{"groupId":"FG001","numSubjects":"2906"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Vaccinated","achievements":[{"groupId":"FG000","numSubjects":"2891"},{"groupId":"FG001","numSubjects":"2891"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1875"},{"groupId":"FG001","numSubjects":"1897"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1034"},{"groupId":"FG001","numSubjects":"1009"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"152"},{"groupId":"FG001","numSubjects":"159"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"39"},{"groupId":"FG001","numSubjects":"33"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"514"},{"groupId":"FG001","numSubjects":"503"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Technical Problems","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"39"},{"groupId":"FG001","numSubjects":"38"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Site terminated by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Study Terminated by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"129"},{"groupId":"FG001","numSubjects":"117"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"80"},{"groupId":"FG001","numSubjects":"83"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Randomized but not vaccinated","reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Initiated prohibited medication","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]}]},{"title":"Revacc Subcohorts (From Day 365 to 730)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"120"},{"groupId":"FG003","numSubjects":"126"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"94"},{"groupId":"FG003","numSubjects":"102"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"26"},{"groupId":"FG003","numSubjects":"24"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Site terminated by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"21"},{"groupId":"FG003","numSubjects":"18"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]}]},{"title":"Revacc Subcohorts (From Day 730 to 1095)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"28"},{"groupId":"FG005","numSubjects":"28"},{"groupId":"FG006","numSubjects":"28"},{"groupId":"FG007","numSubjects":"137"},{"groupId":"FG008","numSubjects":"149"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"28"},{"groupId":"FG005","numSubjects":"24"},{"groupId":"FG006","numSubjects":"28"},{"groupId":"FG007","numSubjects":"127"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"10"},{"groupId":"FG008","numSubjects":"146"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"5"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Study Terminated by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"107"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Site terminated by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"7"},{"groupId":"FG008","numSubjects":"20"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"4"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]}]},{"title":"Revacc Subcohort (From Day 1095 to 1460)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"37"},{"groupId":"FG010","numSubjects":"37"},{"groupId":"FG011","numSubjects":"37"},{"groupId":"FG012","numSubjects":"131"},{"groupId":"FG013","numSubjects":"119"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"37"},{"groupId":"FG010","numSubjects":"37"},{"groupId":"FG011","numSubjects":"37"},{"groupId":"FG012","numSubjects":"131"},{"groupId":"FG013","numSubjects":"119"}]}],"dropWithdraws":[{"type":"Study Terminated by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"36"},{"groupId":"FG010","numSubjects":"36"},{"groupId":"FG011","numSubjects":"35"},{"groupId":"FG012","numSubjects":"125"},{"groupId":"FG013","numSubjects":"114"}]},{"type":"Site terminated by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"2"},{"groupId":"FG012","numSubjects":"4"},{"groupId":"FG013","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"3"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The Full Analysis Set (FAS) included all randomized participants with a documented vaccine administration, regardless of the occurrence of protocol deviations.","groups":[{"id":"BG000","title":"Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture)","description":"Adult participants aged greater than or equal to (\\>=) 65 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) (protein mixture) on Day 1. Participants were divided into revaccination subcohorts: 1A, 1B, and 1C. Participants further received revaccination with the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 1A), 2 (Subcohort 1B), and 3 (Subcohort 1C) years, respectively after the first vaccination on Day 1. Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."},{"id":"BG001","title":"Arm 2: Main Cohort: Group 2: Placebo","description":"Adult participants aged \\>=65 years received a single IM injection of placebo on Day 1. Participants were divided into revaccination subcohorts: 2A, 2B, and 2C. Participants further received revaccination with Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 2A), 2 (Subcohort 2B), and 3 (Subcohort 2C) years, respectively after the first vaccination on Day 1. Participants in subcohorts 2A and 2B were additionally re-randomised in three groups at Year 3 and Year 4, respectively, to receive either Ad26.RSV.preF 1\\*10\\^11 vp alone, RSV preF protein 150 mcg alone or the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture). Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"2891"},{"groupId":"BG001","value":"2891"},{"groupId":"BG002","value":"5782"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"71.7","spread":"5.37"},{"groupId":"BG001","value":"71.6","spread":"5.38"},{"groupId":"BG002","value":"71.7","spread":"5.4"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1639"},{"groupId":"BG001","value":"1694"},{"groupId":"BG002","value":"3333"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"1252"},{"groupId":"BG001","value":"1197"},{"groupId":"BG002","value":"2449"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"97"},{"groupId":"BG002","value":"182"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2778"},{"groupId":"BG001","value":"2773"},{"groupId":"BG002","value":"5551"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"49"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"32"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"21"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"169"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"317"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"2658"},{"groupId":"BG001","value":"2690"},{"groupId":"BG002","value":"5348"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"23"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"24"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"UNITED STATES","categories":[{"measurements":[{"groupId":"BG000","value":"2891"},{"groupId":"BG001","value":"2891"},{"groupId":"BG002","value":"5782"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD)","description":"Number of participants with first occurrence of RT-PCR-confirmed RSV mediated LRTD according to case definition-1, 2 and 3 were reported. Case definition 1 was defined as having a new onset or worsening in 3 or more symptoms of lower respiratory tract infection (LRTI) ; Case definition 2 was defined as having a new onset or worsening in greater than or equal to (\\>=) 2 symptoms of LRTI; and Case definition 3 was defined as having a new onset or worsening in \\>=2 OR \\>=1 symptoms of LRTI with \\>=1 systemic symptoms. Systemic symptoms (fatigue/malaise and fever/feverishness) and symptoms of LRTI (cough, shortness of breath, sputum production, wheezing and tachypnea) were collected via the RiiQ. RiiQ symptom scale was a 13-items questionnaire rated on a 4-point scale. Each symptom was rated on a scale of 0 to 3 where 0=None, 1=Mild, 2=Moderate, and 3=Severe. Higher scores indicated greater severity. The total LRTD symptom score was calculated as the mean of the LRTD symptom scores.","populationDescription":"The Per-protocol Efficacy (PPE) population included all randomized and vaccinated participants excluding participants with major protocol deviations expecting to impact the efficacy outcomes. Any participant with an RT-PCR-confirmed RSV-mediated acute respiratory infection (ARI) with onset within 14 days after vaccination and participants who discontinued within 14 days after vaccination were excluded from the PPE population.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From screening (Day 1) up to 9 months","groups":[{"id":"OG000","title":"Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture)","description":"Adult participants aged greater than or equal to (\\>=) 65 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) (protein mixture) on Day 1. Participants were divided into revaccination subcohorts: 1A, 1B, and 1C. Participants further received revaccination with the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 1A), 2 (Subcohort 1B), and 3 (Subcohort 1C) years, respectively after the first vaccination on Day 1. Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."},{"id":"OG001","title":"Arm 2: Main Cohort: Group 2: Placebo","description":"Adult participants aged \\>=65 years received a single IM injection of placebo on Day 1. Participants were divided into revaccination subcohorts: 2A, 2B, and 2C. Participants further received revaccination with Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 2A), 2 (Subcohort 2B), and 3 (Subcohort 2C) years, respectively after the first vaccination on Day 1. Participants in subcohorts 2A and 2B were additionally re-randomised in three groups at Year 3 and Year 4, respectively, to receive either Ad26.RSV.preF 1\\*10\\^11 vp alone, RSV preF protein 150 mcg alone or the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture). Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2791"},{"groupId":"OG001","value":"2801"}]}],"classes":[{"title":"Case Definition-1","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"30"}]}]},{"title":"Case Definition-2","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"40"}]}]},{"title":"Case Definition-3","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"43"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Case Definition 1","nonInferiorityType":"SUPERIORITY","pValue":"0.00004","statisticalMethod":"Poisson regression","paramType":"Event Rate","paramValue":"80.0","ciPctValue":"94.211","ciNumSides":"TWO_SIDED","ciLowerLimit":"52.2","ciUpperLimit":"92.9"},{"groupIds":["OG000","OG001"],"groupDescription":"Case Definition 2","nonInferiorityType":"SUPERIORITY","pValue":"0.00001","statisticalMethod":"Poisson regression","paramType":"Event Rate","paramValue":"75.0","ciPctValue":"94.211","ciNumSides":"TWO_SIDED","ciLowerLimit":"50.1","ciUpperLimit":"88.5"},{"groupIds":["OG000","OG001"],"groupDescription":"Case Definition 3","nonInferiorityType":"SUPERIORITY","pValue":"0.00004","statisticalMethod":"Poisson regression","paramType":"Event Rate","paramValue":"69.8","ciPctValue":"94.211","ciNumSides":"TWO_SIDED","ciLowerLimit":"43.7","ciUpperLimit":"84.7"}]},{"type":"SECONDARY","title":"Main Cohorts: Number of Participants With Any RT-PCR-confirmed RSV Disease","description":"Number of participants with any RT-PCR-confirmed RSV disease were reported. The analysis was based on poisson regression model.","populationDescription":"The PPE population included all randomized and vaccinated participants excluding participants with major protocol deviations expecting to impact the efficacy outcomes. Any participant with an RT-PCR-confirmed RSV-mediated ARI with onset within 14 days after vaccination and participants who discontinued within 14 days after vaccination were excluded from the PPE population.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From screening (Day 1) up to 9 months","groups":[{"id":"OG000","title":"Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture)","description":"Adult participants aged greater than or equal to (\\>=) 65 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) (protein mixture) on Day 1. Participants were divided into revaccination subcohorts: 1A, 1B, and 1C. Participants further received revaccination with the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 1A), 2 (Subcohort 1B), and 3 (Subcohort 1C) years, respectively after the first vaccination on Day 1. Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."},{"id":"OG001","title":"Arm 2: Main Cohort: Group 2: Placebo","description":"Adult participants aged \\>=65 years received a single IM injection of placebo on Day 1. Participants were divided into revaccination subcohorts: 2A, 2B, and 2C. Participants further received revaccination with Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 2A), 2 (Subcohort 2B), and 3 (Subcohort 2C) years, respectively after the first vaccination on Day 1. Participants in subcohorts 2A and 2B were additionally re-randomised in three groups at Year 3 and Year 4, respectively, to receive either Ad26.RSV.preF 1\\*10\\^11 vp alone, RSV preF protein 150 mcg alone or the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture). Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2791"},{"groupId":"OG001","value":"2801"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"43"}]}]}]},{"type":"SECONDARY","title":"Main Cohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers","description":"RSV A2 strain neutralizing antibody titers of the vaccine-induced immune response was assessed through virus neutralization assay.","populationDescription":"Per-protocol Immunogenicity (PPI) population included all randomized and vaccinated participants who were part of the immunogenicity subset and for whom immunogenicity data were available. Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure and 'n' (participants analyzed) signifies the participants evaluable at specified timepoints.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"Days 15, 85, 169, 365","groups":[{"id":"OG000","title":"Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture)","description":"Adult participants aged greater than or equal to (\\>=) 65 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) (protein mixture) on Day 1. Participants were divided into revaccination subcohorts: 1A, 1B, and 1C. Participants further received revaccination with the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 1A), 2 (Subcohort 1B), and 3 (Subcohort 1C) years, respectively after the first vaccination on Day 1. Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."},{"id":"OG001","title":"Arm 2: Main Cohort: Group 2: Placebo","description":"Adult participants aged \\>=65 years received a single IM injection of placebo on Day 1. Participants were divided into revaccination subcohorts: 2A, 2B, and 2C. Participants further received revaccination with Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 2A), 2 (Subcohort 2B), and 3 (Subcohort 2C) years, respectively after the first vaccination on Day 1. Participants in subcohorts 2A and 2B were additionally re-randomised in three groups at Year 3 and Year 4, respectively, to receive either Ad26.RSV.preF 1\\*10\\^11 vp alone, RSV preF protein 150 mcg alone or the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture). Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"96"}]}],"classes":[{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"91"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6761","lowerLimit":"5478","upperLimit":"8346"},{"groupId":"OG001","value":"516","lowerLimit":"443","upperLimit":"602"}]}]},{"title":"Day 85","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"96"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4963","lowerLimit":"4053","upperLimit":"6077"},{"groupId":"OG001","value":"602","lowerLimit":"528","upperLimit":"687"}]}]},{"title":"Day 169","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3057","lowerLimit":"2523","upperLimit":"3703"},{"groupId":"OG001","value":"552","lowerLimit":"489","upperLimit":"623"}]}]},{"title":"Day 365","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"72"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1546","lowerLimit":"1235","upperLimit":"1936"},{"groupId":"OG001","value":"341","lowerLimit":"284","upperLimit":"409"}]}]}]},{"type":"SECONDARY","title":"Revaccination Subcohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers","description":"RSV A2 strain neutralizing antibody titers of the vaccine-induced immune response was assessed through virus neutralization assay.","populationDescription":"PPI set: all randomized and vaccinated participants who were part of immunogenicity subset and for whom immunogenicity data were available. 'N' (number of participants analyzed): participants evaluable for this outcome measure, 'n' (participants analyzed): participants evaluable at specified timepoints and 'n (number analyzed)=0' signifies that none of participants were available for the assessment at specified timepoints. This outcome measure was planned to be analyzed for specified arms only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"Days 15, 365, 379, 393, 449, 730, 737, 744, 758","groups":[{"id":"OG000","title":"Arm 3: Revaccination (ReVacc) Subcohort 1A: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort 1A and received IM injection of the protein mixture at the same dose level on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"OG001","title":"Arm 4: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein Mixture","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"OG002","title":"Arm 5: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.PreF Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 in the revaccination subcohort further received Ad26.RSV.preF 1\\*10\\^11 vp alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG003","title":"Arm 6: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein (protein mixture) on Day 365 in the revaccination subcohort further received RSV preF protein 150 mcg alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG004","title":"Arm 7: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 and 730. Participants were then followed up for safety assessments till Day 1095."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"120"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"27"}]}],"classes":[{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"116"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5508","lowerLimit":"4695","upperLimit":"6460"},{"groupId":"OG001","value":"421","lowerLimit":"374","upperLimit":"475"},{"groupId":"OG002","value":"357","lowerLimit":"281","upperLimit":"454"},{"groupId":"OG003","value":"361","lowerLimit":"291","upperLimit":"448"},{"groupId":"OG004","value":"487","lowerLimit":"383","upperLimit":"620"}]}]},{"title":"Day 365","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"120"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1451","lowerLimit":"1275","upperLimit":"1651"},{"groupId":"OG001","value":"402","lowerLimit":"354","upperLimit":"456"},{"groupId":"OG002","value":"308","lowerLimit":"241","upperLimit":"392"},{"groupId":"OG003","value":"342","lowerLimit":"264","upperLimit":"444"},{"groupId":"OG004","value":"435","lowerLimit":"348","upperLimit":"544"}]}]},{"title":"Day 379","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2075","lowerLimit":"1779","upperLimit":"2420"},{"groupId":"OG001","value":"5416","lowerLimit":"4462","upperLimit":"6573"},{"groupId":"OG002","value":"4289","lowerLimit":"2739","upperLimit":"6717"},{"groupId":"OG003","value":"6117","lowerLimit":"4194","upperLimit":"8922"},{"groupId":"OG004","value":"5114","lowerLimit":"3161","upperLimit":"8275"}]}]},{"title":"Day 393","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"99"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2098","lowerLimit":"1760","upperLimit":"2501"},{"groupId":"OG001","value":"4821","lowerLimit":"3982","upperLimit":"5836"},{"groupId":"OG002","value":"4487","lowerLimit":"3200","upperLimit":"6291"},{"groupId":"OG003","value":"5008","lowerLimit":"3272","upperLimit":"7664"},{"groupId":"OG004","value":"4078","lowerLimit":"2524","upperLimit":"6589"}]}]},{"title":"Day 449","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"105"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2491","lowerLimit":"2183","upperLimit":"2841"},{"groupId":"OG001","value":"4136","lowerLimit":"3483","upperLimit":"4912"},{"groupId":"OG002","value":"3186","lowerLimit":"2290","upperLimit":"4433"},{"groupId":"OG003","value":"4194","lowerLimit":"3108","upperLimit":"5659"},{"groupId":"OG004","value":"3553","lowerLimit":"2557","upperLimit":"4935"}]}]},{"title":"Day 730","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2260","lowerLimit":"1914","upperLimit":"2669"},{"groupId":"OG002","value":"1795","lowerLimit":"1319","upperLimit":"2443"},{"groupId":"OG003","value":"2486","lowerLimit":"1827","upperLimit":"3382"},{"groupId":"OG004","value":"2491","lowerLimit":"1859","upperLimit":"3338"}]}]},{"title":"Day 737","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"2073","lowerLimit":"1415","upperLimit":"3036"},{"groupId":"OG003","value":"2677","lowerLimit":"2125","upperLimit":"3373"},{"groupId":"OG004","value":"3116","lowerLimit":"2303","upperLimit":"4215"}]}]},{"title":"Day 744","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"2542","lowerLimit":"1721","upperLimit":"3753"},{"groupId":"OG003","value":"3115","lowerLimit":"2453","upperLimit":"3954"},{"groupId":"OG004","value":"3812","lowerLimit":"2772","upperLimit":"5242"}]}]},{"title":"Day 758","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"2263","lowerLimit":"1423","upperLimit":"3598"},{"groupId":"OG003","value":"3631","lowerLimit":"2601","upperLimit":"5067"},{"groupId":"OG004","value":"3668","lowerLimit":"2714","upperLimit":"4958"}]}]}]},{"type":"SECONDARY","title":"Revaccination Subcohorts: Geometric Mean Titers (GMTs) of Prefusion F-protein (Pre-F) A Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)","description":"GMTs of preF-A antibodies after the administration of Ad26.RSV.preF-based vaccine as assessed by ELISA were reported.","populationDescription":"PPI set: all randomized and vaccinated participants who were part of immunogenicity subset and for whom immunogenicity data were available. 'N' (number of participants analyzed): participants evaluable for this outcome measure, 'n' (participants analyzed): participants evaluable at specified timepoints and 'n (number analyzed)=0' signifies that none of participants were available for the assessment at specified timepoints. This outcome measure was planned to be analyzed for specified arms only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"Day 15: Arms 3 to 7,13 and 14; Days 365, 379, 393, 449, 533: Arms 3 to 7; Day 730: Arms 4 to 7; Days 737, 744, 758: Arms 5 to 7; Day 1095, 1109: Arms 13 and 14","groups":[{"id":"OG000","title":"Arm 3: Revaccination (ReVacc) Subcohort 1A: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort 1A and received IM injection of the protein mixture at the same dose level on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"OG001","title":"Arm 4: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein Mixture","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"OG002","title":"Arm 5: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.PreF Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 in the revaccination subcohort further received Ad26.RSV.preF 1\\*10\\^11 vp alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG003","title":"Arm 6: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein (protein mixture) on Day 365 in the revaccination subcohort further received RSV preF protein 150 mcg alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG004","title":"Arm 7: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 and 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG005","title":"Arm 13: ReVacc Subcohort 1C: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG006","title":"Arm 14: ReVacc Subcohort 2C: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1095. Participants were then followed up for safety assessments till Day 1460."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"120"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"127"},{"groupId":"OG006","value":"114"}]}],"classes":[{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"116"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"125"},{"groupId":"OG006","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4091","lowerLimit":"3540","upperLimit":"4728"},{"groupId":"OG001","value":"301","lowerLimit":"269","upperLimit":"336"},{"groupId":"OG002","value":"258","lowerLimit":"203","upperLimit":"328"},{"groupId":"OG003","value":"282","lowerLimit":"228","upperLimit":"349"},{"groupId":"OG004","value":"391","lowerLimit":"307","upperLimit":"497"},{"groupId":"OG005","value":"4195","lowerLimit":"3685","upperLimit":"4776"},{"groupId":"OG006","value":"279","lowerLimit":"238","upperLimit":"326"}]}]},{"title":"Day 365","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"120"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1003","lowerLimit":"901","upperLimit":"1117"},{"groupId":"OG001","value":"325","lowerLimit":"293","upperLimit":"361"},{"groupId":"OG002","value":"259","lowerLimit":"200","upperLimit":"335"},{"groupId":"OG003","value":"317","lowerLimit":"259","upperLimit":"388"},{"groupId":"OG004","value":"358","lowerLimit":"291","upperLimit":"440"}]}]},{"title":"Day 379","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1688","lowerLimit":"1487","upperLimit":"1917"},{"groupId":"OG001","value":"4402","lowerLimit":"3807","upperLimit":"5089"},{"groupId":"OG002","value":"3642","lowerLimit":"2582","upperLimit":"5136"},{"groupId":"OG003","value":"4827","lowerLimit":"3545","upperLimit":"6572"},{"groupId":"OG004","value":"4290","lowerLimit":"3069","upperLimit":"5996"}]}]},{"title":"Day 393","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"99"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1757","lowerLimit":"1549","upperLimit":"1994"},{"groupId":"OG001","value":"3793","lowerLimit":"3265","upperLimit":"4405"},{"groupId":"OG002","value":"3408","lowerLimit":"2578","upperLimit":"4505"},{"groupId":"OG003","value":"4341","lowerLimit":"3072","upperLimit":"6134"},{"groupId":"OG004","value":"3541","lowerLimit":"2473","upperLimit":"5070"}]}]},{"title":"Day 449","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"105"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1534","lowerLimit":"1376","upperLimit":"1710"},{"groupId":"OG001","value":"2513","lowerLimit":"2172","upperLimit":"2908"},{"groupId":"OG002","value":"2227","lowerLimit":"1671","upperLimit":"2968"},{"groupId":"OG003","value":"2999","lowerLimit":"2254","upperLimit":"3991"},{"groupId":"OG004","value":"2129","lowerLimit":"1509","upperLimit":"3002"}]}]},{"title":"Day 533","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"99"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1430","lowerLimit":"1287","upperLimit":"1590"},{"groupId":"OG001","value":"1818","lowerLimit":"1585","upperLimit":"2086"},{"groupId":"OG002","value":"1605","lowerLimit":"1132","upperLimit":"2275"},{"groupId":"OG003","value":"1835","lowerLimit":"1429","upperLimit":"2358"},{"groupId":"OG004","value":"1783","lowerLimit":"1350","upperLimit":"2355"}]}]},{"title":"Day 730","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1270","lowerLimit":"1112","upperLimit":"1451"},{"groupId":"OG002","value":"992","lowerLimit":"767","upperLimit":"1283"},{"groupId":"OG003","value":"1467","lowerLimit":"1182","upperLimit":"1822"},{"groupId":"OG004","value":"1379","lowerLimit":"1099","upperLimit":"1732"}]}]},{"title":"Day 737","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"1138","lowerLimit":"850","upperLimit":"1524"},{"groupId":"OG003","value":"1779","lowerLimit":"1510","upperLimit":"2096"},{"groupId":"OG004","value":"1674","lowerLimit":"1348","upperLimit":"2077"}]}]},{"title":"Day 744","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"1352","lowerLimit":"1111","upperLimit":"1644"},{"groupId":"OG003","value":"2001","lowerLimit":"1619","upperLimit":"2473"},{"groupId":"OG004","value":"2181","lowerLimit":"1714","upperLimit":"2774"}]}]},{"title":"Day 758","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"1436","lowerLimit":"1049","upperLimit":"1964"},{"groupId":"OG003","value":"2331","lowerLimit":"1786","upperLimit":"3043"},{"groupId":"OG004","value":"2131","lowerLimit":"1666","upperLimit":"2726"}]}]},{"title":"Day 1095","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"127"},{"groupId":"OG006","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"825","lowerLimit":"743","upperLimit":"917"},{"groupId":"OG006","value":"317","lowerLimit":"276","upperLimit":"363"}]}]},{"title":"Day 1109","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"108"},{"groupId":"OG006","value":"96"}]}],"categories":[{"measurements":[{"groupId":"OG005","value":"2152","lowerLimit":"1923","upperLimit":"2407"},{"groupId":"OG006","value":"3736","lowerLimit":"3196","upperLimit":"4367"}]}]}]},{"type":"SECONDARY","title":"Revaccination Subcohort 2A: T-cell Interferon (IFN) Gamma Responses to RSV F Protein Peptides Analyzed by Enzyme-linked Immunospot Assay (ELISpot)","description":"T-cell IFN gamma responses to RSV F protein specific peptides as measured by ELISpot assay were reported. RSV F protein specific T-cell IFN gamma ELISpot responses were measured as counts of spot forming cells per million peripheral blood mononuclear cells (SFC/10\\^6 PBMCs).","populationDescription":"PPI population included all randomized and vaccinated participants who were part of the immuno subset and for whom immunogenicity data were available. Here, 'N' (Overall number of participants analyzed) signifies participants who were evaluable for this outcome measure. Here, 'n' signifies participants evaluable for specified timepoints. This outcome measure was planned to be analyzed for specified arms only.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"SFC/10^6 PBMCs","timeFrame":"Days 730, 744, 758","groups":[{"id":"OG000","title":"Arm 5: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.PreF Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 in the revaccination subcohort further received Ad26.RSV.preF 1\\*10\\^11 vp alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG001","title":"Arm 6: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein (protein mixture) on Day 365 in the revaccination subcohort further received RSV preF protein 150 mcg alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG002","title":"Arm 7: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 and 730. Participants were then followed up for safety assessments till Day 1095."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"16"}]}],"classes":[{"title":"Day 730","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"129","lowerLimit":"34","upperLimit":"320"},{"groupId":"OG001","value":"198","lowerLimit":"34","upperLimit":"1035"},{"groupId":"OG002","value":"168","lowerLimit":"34","upperLimit":"795"}]}]},{"title":"Day 744","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"402","lowerLimit":"105","upperLimit":"1420"},{"groupId":"OG001","value":"498","lowerLimit":"130","upperLimit":"2269"},{"groupId":"OG002","value":"405","lowerLimit":"34","upperLimit":"3104"}]}]},{"title":"Day 758","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"278","lowerLimit":"84","upperLimit":"443"},{"groupId":"OG001","value":"484","lowerLimit":"196","upperLimit":"1375"},{"groupId":"OG002","value":"277","lowerLimit":"34","upperLimit":"1253"}]}]}]},{"type":"SECONDARY","title":"Main Cohorts: T-cell Interferon (IFN) Gamma Responses to RSV F Protein Peptides Analyzed by Enzyme-linked Immunospot Assay (ELISpot)","description":"T-cell IFN gamma responses to RSV F protein specific peptides as measured by ELISpot assay were reported. RSV F protein specific T-cell IFN gamma ELISpot responses were measured as counts of spot forming cells per million peripheral blood mononuclear cells (SFC/10\\^6 PBMCs).","populationDescription":"PPI population included all randomized and vaccinated participants who were part of the immuno subset and for whom immunogenicity data were available. Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure. Here, 'n' signifies participants evaluable for specified timepoints.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"SFC/10^6 PBMCs","timeFrame":"Days 15, 85, 169, 365, 533","groups":[{"id":"OG000","title":"Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture)","description":"Adult participants aged greater than or equal to (\\>=) 65 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) (protein mixture) on Day 1. Participants were divided into revaccination subcohorts: 1A, 1B, and 1C. Participants further received revaccination with the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 1A), 2 (Subcohort 1B), and 3 (Subcohort 1C) years, respectively after the first vaccination on Day 1. Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."},{"id":"OG001","title":"Arm 2: Main Cohort: Group 2: Placebo","description":"Adult participants aged \\>=65 years received a single IM injection of placebo on Day 1. Participants were divided into revaccination subcohorts: 2A, 2B, and 2C. Participants further received revaccination with Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 2A), 2 (Subcohort 2B), and 3 (Subcohort 2C) years, respectively after the first vaccination on Day 1. Participants in subcohorts 2A and 2B were additionally re-randomised in three groups at Year 3 and Year 4, respectively, to receive either Ad26.RSV.preF 1\\*10\\^11 vp alone, RSV preF protein 150 mcg alone or the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture). Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"87"}]}],"classes":[{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"76"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"444","lowerLimit":"279","upperLimit":"641"},{"groupId":"OG001","value":"34","lowerLimit":"34","upperLimit":"34"}]}]},{"title":"Day 85","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"87"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"274","lowerLimit":"173","upperLimit":"471"},{"groupId":"OG001","value":"34","lowerLimit":"34","upperLimit":"34"}]}]},{"title":"Day 169","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"87"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"201","lowerLimit":"123","upperLimit":"324"},{"groupId":"OG001","value":"34","lowerLimit":"34","upperLimit":"34"}]}]},{"title":"Day 365","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"182","lowerLimit":"110","upperLimit":"297"},{"groupId":"OG001","value":"34","lowerLimit":"34","upperLimit":"34"}]}]},{"title":"Day 533","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"56"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"143","lowerLimit":"96","upperLimit":"238"},{"groupId":"OG001","value":"34","lowerLimit":"34","upperLimit":"74"}]}]}]},{"type":"SECONDARY","title":"Main Cohorts: Number of Participants With Solicited Local Adverse Events (AEs) up to 7 Days After First Vaccination","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Solicited local AEs were precisely defined events that participants were specifically asked about and which were noted by participants in the diary. Solicited local AEs included erythema, swelling/induration, and pain/tenderness. Per protocol, all solicited local AEs were considered as related to intervention.","populationDescription":"The safety subset included all participants that consented to the collection of AEs (solicited AEs for up to 7 days after vaccination and unsolicited AEs for 28 days after vaccination). Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 8 (7 days after first vaccination on Day 1)","groups":[{"id":"OG000","title":"Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture)","description":"Adult participants aged greater than or equal to (\\>=) 65 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) (protein mixture) on Day 1. Participants were divided into revaccination subcohorts: 1A, 1B, and 1C. Participants further received revaccination with the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 1A), 2 (Subcohort 1B), and 3 (Subcohort 1C) years, respectively after the first vaccination on Day 1. Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."},{"id":"OG001","title":"Arm 2: Main Cohort: Group 2: Placebo","description":"Adult participants aged \\>=65 years received a single IM injection of placebo on Day 1. Participants were divided into revaccination subcohorts: 2A, 2B, and 2C. Participants further received revaccination with Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 2A), 2 (Subcohort 2B), and 3 (Subcohort 2C) years, respectively after the first vaccination on Day 1. Participants in subcohorts 2A and 2B were additionally re-randomised in three groups at Year 3 and Year 4, respectively, to receive either Ad26.RSV.preF 1\\*10\\^11 vp alone, RSV preF protein 150 mcg alone or the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture). Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"},{"groupId":"OG001","value":"334"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"29"}]}]}]},{"type":"SECONDARY","title":"Main Cohorts: Number of Participants With Solicited Systemic AEs up to 7 Days After First Vaccination","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Solicited systemic AEs included fatigue, headache, myalgia, arthralgia, and fever (defined as an endogenous elevation of body temperature \\>=38.0°C, as recorded in at least one measurement).","populationDescription":"The safety subset included all participants that consented to the collection of AEs (solicited AEs for up to 7 days after vaccination and unsolicited AEs for 28 days after vaccination). Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 8 (7 days after first vaccination on Day 1)","groups":[{"id":"OG000","title":"Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture)","description":"Adult participants aged greater than or equal to (\\>=) 65 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) (protein mixture) on Day 1. Participants were divided into revaccination subcohorts: 1A, 1B, and 1C. Participants further received revaccination with the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 1A), 2 (Subcohort 1B), and 3 (Subcohort 1C) years, respectively after the first vaccination on Day 1. Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."},{"id":"OG001","title":"Arm 2: Main Cohort: Group 2: Placebo","description":"Adult participants aged \\>=65 years received a single IM injection of placebo on Day 1. Participants were divided into revaccination subcohorts: 2A, 2B, and 2C. Participants further received revaccination with Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 2A), 2 (Subcohort 2B), and 3 (Subcohort 2C) years, respectively after the first vaccination on Day 1. Participants in subcohorts 2A and 2B were additionally re-randomised in three groups at Year 3 and Year 4, respectively, to receive either Ad26.RSV.preF 1\\*10\\^11 vp alone, RSV preF protein 150 mcg alone or the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture). Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"},{"groupId":"OG001","value":"334"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"58"}]}]}]},{"type":"SECONDARY","title":"Main Cohorts: Number of Participants With Unsolicited AEs up to 28 Days After First Vaccination","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Unsolicited adverse events included all adverse events for which the participant is not specifically questioned in the participant diary.","populationDescription":"The safety subset included all participants that consented to the collection of AEs (solicited AEs for up to 7 days after vaccination and unsolicited AEs for 28 days after vaccination).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 29 (28 days after first vaccination on Day 1)","groups":[{"id":"OG000","title":"Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture)","description":"Adult participants aged greater than or equal to (\\>=) 65 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) (protein mixture) on Day 1. Participants were divided into revaccination subcohorts: 1A, 1B, and 1C. Participants further received revaccination with the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 1A), 2 (Subcohort 1B), and 3 (Subcohort 1C) years, respectively after the first vaccination on Day 1. Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."},{"id":"OG001","title":"Arm 2: Main Cohort: Group 2: Placebo","description":"Adult participants aged \\>=65 years received a single IM injection of placebo on Day 1. Participants were divided into revaccination subcohorts: 2A, 2B, and 2C. Participants further received revaccination with Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 2A), 2 (Subcohort 2B), and 3 (Subcohort 2C) years, respectively after the first vaccination on Day 1. Participants in subcohorts 2A and 2B were additionally re-randomised in three groups at Year 3 and Year 4, respectively, to receive either Ad26.RSV.preF 1\\*10\\^11 vp alone, RSV preF protein 150 mcg alone or the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture). Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"347"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"50"}]}]}]},{"type":"SECONDARY","title":"Revaccination Subcohorts: Number of Participants With Solicited Local AEs 7 Days After Re-vaccination up to 1, 2 and 3 Years","description":"Number of participants with solicited local AEs 7 days after re-vaccination at 1, 2 and 3 years were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Solicited local AEs were precisely defined events that participants were specifically asked about and which were noted by participants in the diary. Solicited local AEs included erythema, swelling/induration, and pain/tenderness. Per protocol, all solicited local AEs were considered as related to intervention.","populationDescription":"The Full Analysis Set (FAS) included all randomized participants with a documented vaccine administration, regardless of the occurrence of protocol deviations. Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Arms 3,4: 7 days after revacc at 1 year (up to Day 372); Arm 5,6,7,8,9: 7 days after revacc at 2 years (up to Day 737); Arms 10,11,12,13,14: 7 days after revacc at 3 year (up to Day 1102)","groups":[{"id":"OG000","title":"Arm 3: Revaccination (ReVacc) Subcohort 1A: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort 1A and received IM injection of the protein mixture at the same dose level on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"OG001","title":"Arm 4: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein Mixture","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"OG002","title":"Arm 5: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.PreF Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 in the revaccination subcohort further received Ad26.RSV.preF 1\\*10\\^11 vp alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG003","title":"Arm 6: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein (protein mixture) on Day 365 in the revaccination subcohort further received RSV preF protein 150 mcg alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG004","title":"Arm 7: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 and 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG005","title":"Arm 8: ReVacc Subcohort 1B: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG006","title":"Arm 9: ReVacc Subcohort 2B:Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG007","title":"Arm 10: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.preF","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by Ad26.RSV.preF 1\\*10\\^11 vp alone on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG008","title":"Arm 11: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by RSV preF protein 150 mcg alone on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG009","title":"Arm 12: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Days 730 and Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG010","title":"Arm 13: ReVacc Subcohort 1C: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG011","title":"Arm 14: ReVacc Subcohort 2C: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1095. Participants were then followed up for safety assessments till Day 1460."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"126"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"137"},{"groupId":"OG006","value":"149"},{"groupId":"OG007","value":"37"},{"groupId":"OG008","value":"36"},{"groupId":"OG009","value":"37"},{"groupId":"OG010","value":"131"},{"groupId":"OG011","value":"118"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"97"},{"groupId":"OG006","value":"81"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"17"},{"groupId":"OG009","value":"29"},{"groupId":"OG010","value":"93"},{"groupId":"OG011","value":"64"}]}]}]},{"type":"SECONDARY","title":"Revaccination Subcohorts: Number of Participants With Solicited Systemic AEs 7 Days After Re-vaccination up to 1, 2 and 3 Years","description":"Number of participants with solicited systemic AEs 7 days after re-vaccination up to 1, 2 and 3 years were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Solicited systemic AEs included fatigue, headache, myalgia, arthralgia, and fever (defined as an endogenous elevation of body temperature \\>=38.0°C, as recorded in at least one measurement).","populationDescription":"The FAS included all randomized participants with a documented vaccine administration, regardless of the occurrence of protocol deviations. Here, 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Arms 3,4: 7 days after revacc at 1 year (up to Day 372); Arm 5,6,7,8,9: 7 days after revacc at 2 years (up to Day 737); Arms 10,11,12,13,14: 7 days after revacc at 3 year (up to Day 1102)","groups":[{"id":"OG000","title":"Arm 3: Revaccination (ReVacc) Subcohort 1A: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort 1A and received IM injection of the protein mixture at the same dose level on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"OG001","title":"Arm 4: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein Mixture","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"OG002","title":"Arm 5: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.PreF Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 in the revaccination subcohort further received Ad26.RSV.preF 1\\*10\\^11 vp alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG003","title":"Arm 6: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein (protein mixture) on Day 365 in the revaccination subcohort further received RSV preF protein 150 mcg alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG004","title":"Arm 7: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 and 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG005","title":"Arm 8: ReVacc Subcohort 1B: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG006","title":"Arm 9: ReVacc Subcohort 2B:Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG007","title":"Arm 10: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.preF","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by Ad26.RSV.preF 1\\*10\\^11 vp alone on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG008","title":"Arm 11: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by RSV preF protein 150 mcg alone on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG009","title":"Arm 12: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Days 730 and Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG010","title":"Arm 13: ReVacc Subcohort 1C: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG011","title":"Arm 14: ReVacc Subcohort 2C: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1095. Participants were then followed up for safety assessments till Day 1460."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"126"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"137"},{"groupId":"OG006","value":"149"},{"groupId":"OG007","value":"37"},{"groupId":"OG008","value":"36"},{"groupId":"OG009","value":"37"},{"groupId":"OG010","value":"131"},{"groupId":"OG011","value":"118"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"79"},{"groupId":"OG006","value":"85"},{"groupId":"OG007","value":"16"},{"groupId":"OG008","value":"12"},{"groupId":"OG009","value":"25"},{"groupId":"OG010","value":"80"},{"groupId":"OG011","value":"70"}]}]}]},{"type":"SECONDARY","title":"Revaccination Subcohorts: Number of Participants With Unsolicited AEs 28 Days After Re-vaccination up to 1, 2 and 3 Years","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Unsolicited adverse events included all adverse events for which the participant is not specifically questioned in the participant diary.","populationDescription":"The FAS included all randomized participants with a documented vaccine administration, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Arms 3,4: 28 days after revacc at 1 year (up to Day 393); Arms 5,6,7,8,9: 28 days after revacc at 2 years (up to Day 758); Arms 10,11,12,13,14: 28 days after revaccination at 3 year (up to Day 1123)","groups":[{"id":"OG000","title":"Arm 3: Revaccination (ReVacc) Subcohort 1A: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort 1A and received IM injection of the protein mixture at the same dose level on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"OG001","title":"Arm 4: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein Mixture","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"OG002","title":"Arm 5: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.PreF Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 in the revaccination subcohort further received Ad26.RSV.preF 1\\*10\\^11 vp alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG003","title":"Arm 6: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein (protein mixture) on Day 365 in the revaccination subcohort further received RSV preF protein 150 mcg alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG004","title":"Arm 7: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 and 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG005","title":"Arm 8: ReVacc Subcohort 1B: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG006","title":"Arm 9: ReVacc Subcohort 2B:Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG007","title":"Arm 10: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.preF","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by Ad26.RSV.preF 1\\*10\\^11 vp alone on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG008","title":"Arm 11: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by RSV preF protein 150 mcg alone on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG009","title":"Arm 12: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Days 730 and Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG010","title":"Arm 13: ReVacc Subcohort 1C: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG011","title":"Arm 14: ReVacc Subcohort 2C: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1095. Participants were then followed up for safety assessments till Day 1460."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"126"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"137"},{"groupId":"OG006","value":"149"},{"groupId":"OG007","value":"37"},{"groupId":"OG008","value":"37"},{"groupId":"OG009","value":"37"},{"groupId":"OG010","value":"131"},{"groupId":"OG011","value":"119"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"16"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"11"},{"groupId":"OG011","value":"10"}]}]}]},{"type":"SECONDARY","title":"Revaccination Subcohorts: Number of Participants With Adverse Events of Special Interests (AESI)","description":"Number of participants with AESIs were reported. An AE was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Thrombosis with thrombocytopenia syndrome (TTS) was considered as an AESI.","populationDescription":"The FAS included all randomized participants with a documented vaccine administration, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Arms 3,4: 6 months after revacc at 1 year (up to Day 547); Arm 5,6,7,8,9: 6 months after revacc at 2 years (up to Day 912); Arms 10,11,12,13,14: 6 months after revacc at 3 year (up to Day 1277)","groups":[{"id":"OG000","title":"Arm 3: Revaccination (ReVacc) Subcohort 1A: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort 1A and received IM injection of the protein mixture at the same dose level on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"OG001","title":"Arm 4: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein Mixture","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"OG002","title":"Arm 5: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.PreF Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 in the revaccination subcohort further received Ad26.RSV.preF 1\\*10\\^11 vp alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG003","title":"Arm 6: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein (protein mixture) on Day 365 in the revaccination subcohort further received RSV preF protein 150 mcg alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG004","title":"Arm 7: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 and 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG005","title":"Arm 8: ReVacc Subcohort 1B: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG006","title":"Arm 9: ReVacc Subcohort 2B:Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG007","title":"Arm 10: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.preF","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by Ad26.RSV.preF 1\\*10\\^11 vp alone on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG008","title":"Arm 11: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by RSV preF protein 150 mcg alone on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG009","title":"Arm 12: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Days 730 and Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG010","title":"Arm 13: ReVacc Subcohort 1C: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG011","title":"Arm 14: ReVacc Subcohort 2C: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1095. Participants were then followed up for safety assessments till Day 1460."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"126"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"137"},{"groupId":"OG006","value":"149"},{"groupId":"OG007","value":"37"},{"groupId":"OG008","value":"37"},{"groupId":"OG009","value":"37"},{"groupId":"OG010","value":"131"},{"groupId":"OG011","value":"119"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]}]},{"type":"SECONDARY","title":"Main Cohorts:Number of Participants With Serious Adverse Events (SAEs)","description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. For participants who were not revaccinated only SAEs associated with ARIs and complications related to ARIs that classify as SAEs, SAEs classified as related, SAEs resulting in death, and (S)AEs resulting in study discontinuation or from procedures and non-investigational (concomitant) Janssen products were collected.","populationDescription":"The FAS included all randomized participants with a documented vaccine administration, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 1 up to Day 1095","groups":[{"id":"OG000","title":"Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture)","description":"Adult participants aged greater than or equal to (\\>=) 65 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) (protein mixture) on Day 1. Participants were divided into revaccination subcohorts: 1A, 1B, and 1C. Participants further received revaccination with the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 1A), 2 (Subcohort 1B), and 3 (Subcohort 1C) years, respectively after the first vaccination on Day 1. Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."},{"id":"OG001","title":"Arm 2: Main Cohort: Group 2: Placebo","description":"Adult participants aged \\>=65 years received a single IM injection of placebo on Day 1. Participants were divided into revaccination subcohorts: 2A, 2B, and 2C. Participants further received revaccination with Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 2A), 2 (Subcohort 2B), and 3 (Subcohort 2C) years, respectively after the first vaccination on Day 1. Participants in subcohorts 2A and 2B were additionally re-randomised in three groups at Year 3 and Year 4, respectively, to receive either Ad26.RSV.preF 1\\*10\\^11 vp alone, RSV preF protein 150 mcg alone or the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture). Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2891"},{"groupId":"OG001","value":"2891"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"196"}]}]}]},{"type":"SECONDARY","title":"Revaccination Subcohorts: Number of Participants With Serious Adverse Events (SAEs)","description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","populationDescription":"The FAS included all randomized participants with a documented vaccine administration, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Arms 3,4: 6 months after revacc at 1 year (up to Day 547); Arm 5,6,7,8,9: 6 months after revacc at 2 years (up to Day 912); Arms 10,11,12,13,14: 6 months after revacc at 3 year (up to Day 1277)","groups":[{"id":"OG000","title":"Arm 3: Revaccination (ReVacc) Subcohort 1A: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort 1A and received IM injection of the protein mixture at the same dose level on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"OG001","title":"Arm 4: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein Mixture","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365. Participants were then followed up for safety assessments till Day 730."},{"id":"OG002","title":"Arm 5: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.PreF Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 in the revaccination subcohort further received Ad26.RSV.preF 1\\*10\\^11 vp alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG003","title":"Arm 6: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein (protein mixture) on Day 365 in the revaccination subcohort further received RSV preF protein 150 mcg alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG004","title":"Arm 7: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 and 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG005","title":"Arm 8: ReVacc Subcohort 1B: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG006","title":"Arm 9: ReVacc Subcohort 2B:Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730. Participants were then followed up for safety assessments till Day 1095."},{"id":"OG007","title":"Arm 10: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.preF","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by Ad26.RSV.preF 1\\*10\\^11 vp alone on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG008","title":"Arm 11: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by RSV preF protein 150 mcg alone on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG009","title":"Arm 12: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Days 730 and Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG010","title":"Arm 13: ReVacc Subcohort 1C: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 1095. Participants were then followed up for safety assessments till Day 1460."},{"id":"OG011","title":"Arm 14: ReVacc Subcohort 2C: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1095. Participants were then followed up for safety assessments till Day 1460."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"126"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"137"},{"groupId":"OG006","value":"149"},{"groupId":"OG007","value":"37"},{"groupId":"OG008","value":"37"},{"groupId":"OG009","value":"37"},{"groupId":"OG010","value":"131"},{"groupId":"OG011","value":"119"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"2"}]}]}]},{"type":"SECONDARY","title":"Main Cohorts: Geometric Mean Titers (GMTs) of Prefusion F-protein (Pre-F) A Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)","description":"GMTs of preF-A antibodies after the administration of Ad26.RSV.preF-based vaccine as assessed by ELISA were reported.","populationDescription":"PPI: all randomized and vaccinated participants who were part of immunogenicity subset and for whom immunogenicity data were available. Here, 'N' (Overall number of participants analyzed)=participants who were evaluable for this outcome measure, \"n\"=participants evaluable for specific timepoints.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"Days 15, 85, 169, 365, 533","groups":[{"id":"OG000","title":"Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture)","description":"Adult participants aged greater than or equal to (\\>=) 65 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) (protein mixture) on Day 1. Participants were divided into revaccination subcohorts: 1A, 1B, and 1C. Participants further received revaccination with the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 1A), 2 (Subcohort 1B), and 3 (Subcohort 1C) years, respectively after the first vaccination on Day 1. Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."},{"id":"OG001","title":"Arm 2: Main Cohort: Group 2: Placebo","description":"Adult participants aged \\>=65 years received a single IM injection of placebo on Day 1. Participants were divided into revaccination subcohorts: 2A, 2B, and 2C. Participants further received revaccination with Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 2A), 2 (Subcohort 2B), and 3 (Subcohort 2C) years, respectively after the first vaccination on Day 1. Participants in subcohorts 2A and 2B were additionally re-randomised in three groups at Year 3 and Year 4, respectively, to receive either Ad26.RSV.preF 1\\*10\\^11 vp alone, RSV preF protein 150 mcg alone or the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture). Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"96"}]}],"classes":[{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"91"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4001","lowerLimit":"3354","upperLimit":"4772"},{"groupId":"OG001","value":"305","lowerLimit":"256","upperLimit":"364"}]}]},{"title":"Day 85","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"96"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2475","lowerLimit":"2129","upperLimit":"2876"},{"groupId":"OG001","value":"359","lowerLimit":"302","upperLimit":"426"}]}]},{"title":"Day 169","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1604","lowerLimit":"1381","upperLimit":"1863"},{"groupId":"OG001","value":"335","lowerLimit":"293","upperLimit":"383"}]}]},{"title":"Day 365","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"72"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1044","lowerLimit":"908","upperLimit":"1201"},{"groupId":"OG001","value":"281","lowerLimit":"237","upperLimit":"334"}]}]},{"title":"Day 533","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"991","lowerLimit":"863","upperLimit":"1137"},{"groupId":"OG001","value":"315","lowerLimit":"267","upperLimit":"371"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"All-cause mortality: Day 1 to Day 1095 (Arms 1, 2); Day 365 to Day 730 (Arms 3, 4); Day 730 to Day 1095 (Arms 5 to 9); Day 1095 to Day 1460 (Arms 10 to 14); Serious/other AEs: Day 1 to Day 1095 (Arms 1, 2), 6 months after revacc at Day 365 (Arms 3, 4): up to Day 547, 6 months after revacc at Day 730 (Arms 5 to 9): up to Day 912, 6 months after revacc at Day 1095 (Arms 10 to 14): up to Day 1277","description":"All-cause mortality and SAEs analyzed based on FAS population which included all randomized participants with a documented vaccine administration, regardless of occurrence of protocol deviations. Other (not including serious) AEs as solicited and unsolicited AEs were collected and analyzed in safety subset (subset of FAS) for main cohorts and in FAS for revaccination subcohorts. The safety subset included all participants that consented to the collection of AEs (solicited and unsolicited AEs).","eventGroups":[{"id":"EG000","title":"Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture)","description":"Adult participants aged greater than or equal to (\\>=) 65 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) (protein mixture) on Day 1. Participants were divided into revaccination subcohorts: 1A, 1B, and 1C. Participants further received revaccination with the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 1A), 2 (Subcohort 1B), and 3 (Subcohort 1C) years, respectively after the first vaccination on Day 1. Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095.","deathsNumAffected":39,"deathsNumAtRisk":2891,"seriousNumAffected":203,"seriousNumAtRisk":2891,"otherNumAffected":186,"otherNumAtRisk":348},{"id":"EG001","title":"Arm 2: Main Cohort: Group 2: Placebo","description":"Adult participants aged \\>=65 years received a single IM injection of placebo on Day 1. Participants were divided into revaccination subcohorts: 2A, 2B, and 2C. Participants further received revaccination with Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) at 1 (Subcohort 2A), 2 (Subcohort 2B), and 3 (Subcohort 2C) years, respectively after the first vaccination on Day 1. Participants in subcohorts 2A and 2B were additionally re-randomised in three groups at Year 3 and Year 4, respectively, to receive either Ad26.RSV.preF 1\\*10\\^11 vp alone, RSV preF protein 150 mcg alone or the Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture). Participants who were not re-vaccinated continued in the main cohort and were followed up for safety assessments until Day 1095.","deathsNumAffected":38,"deathsNumAtRisk":2891,"seriousNumAffected":196,"seriousNumAtRisk":2891,"otherNumAffected":90,"otherNumAtRisk":347},{"id":"EG002","title":"Arm 3: Revaccination (ReVacc) Subcohort 1A: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort 1A and received IM injection of the protein mixture at the same dose level on Day 365. Participants were then followed up for safety assessments till Day 730.","deathsNumAffected":1,"deathsNumAtRisk":120,"seriousNumAffected":2,"seriousNumAtRisk":120,"otherNumAffected":47,"otherNumAtRisk":120},{"id":"EG003","title":"Arm 4: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein Mixture","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365. Participants were then followed up for safety assessments till Day 730.","deathsNumAffected":0,"deathsNumAtRisk":126,"seriousNumAffected":6,"seriousNumAtRisk":126,"otherNumAffected":47,"otherNumAtRisk":126},{"id":"EG004","title":"Arm 5: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.PreF Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 in the revaccination subcohort further received Ad26.RSV.preF 1\\*10\\^11 vp alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095.","deathsNumAffected":0,"deathsNumAtRisk":28,"seriousNumAffected":0,"seriousNumAtRisk":28,"otherNumAffected":15,"otherNumAtRisk":28},{"id":"EG005","title":"Arm 6: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort followed by Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein (protein mixture) on Day 365 in the revaccination subcohort further received RSV preF protein 150 mcg alone as IM injection on Day 730. Participants were then followed up for safety assessments till Day 1095.","deathsNumAffected":0,"deathsNumAtRisk":28,"seriousNumAffected":3,"seriousNumAtRisk":28,"otherNumAffected":21,"otherNumAtRisk":28},{"id":"EG006","title":"Arm 7: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main study cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 365 and 730. Participants were then followed up for safety assessments till Day 1095.","deathsNumAffected":0,"deathsNumAtRisk":28,"seriousNumAffected":1,"seriousNumAtRisk":28,"otherNumAffected":21,"otherNumAtRisk":28},{"id":"EG007","title":"Arm 8: ReVacc Subcohort 1B: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 730. Participants were then followed up for safety assessments till Day 1095.","deathsNumAffected":0,"deathsNumAtRisk":137,"seriousNumAffected":4,"seriousNumAtRisk":137,"otherNumAffected":110,"otherNumAtRisk":137},{"id":"EG008","title":"Arm 9: ReVacc Subcohort 2B:Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730. Participants were then followed up for safety assessments till Day 1095.","deathsNumAffected":2,"deathsNumAtRisk":149,"seriousNumAffected":6,"seriousNumAtRisk":149,"otherNumAffected":111,"otherNumAtRisk":149},{"id":"EG009","title":"Arm 10: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.preF","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by Ad26.RSV.preF 1\\*10\\^11 vp alone on Day 1095. Participants were then followed up for safety assessments till Day 1460.","deathsNumAffected":0,"deathsNumAtRisk":37,"seriousNumAffected":2,"seriousNumAtRisk":37,"otherNumAffected":30,"otherNumAtRisk":37},{"id":"EG010","title":"Arm 11: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 730 followed by RSV preF protein 150 mcg alone on Day 1095. Participants were then followed up for safety assessments till Day 1460.","deathsNumAffected":0,"deathsNumAtRisk":37,"seriousNumAffected":0,"seriousNumAtRisk":37,"otherNumAffected":22,"otherNumAtRisk":37},{"id":"EG011","title":"Arm 12: ReVacc Subcohort 2B: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Days 730 and Day 1095. Participants were then followed up for safety assessments till Day 1460.","deathsNumAffected":0,"deathsNumAtRisk":37,"seriousNumAffected":0,"seriousNumAtRisk":37,"otherNumAffected":34,"otherNumAtRisk":37},{"id":"EG012","title":"Arm 13: ReVacc Subcohort 1C: Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1 in the main cohort entered the revaccination subcohort and received the protein mixture at the same dose level on Day 1095. Participants were then followed up for safety assessments till Day 1460.","deathsNumAffected":0,"deathsNumAtRisk":131,"seriousNumAffected":2,"seriousNumAtRisk":131,"otherNumAffected":107,"otherNumAtRisk":131},{"id":"EG013","title":"Arm 14: ReVacc Subcohort 2C: Placebo to Ad26.RSV.preF/RSV preF Protein (Protein Mixture)","description":"Eligible participants who received IM injection of placebo on Day 1 in the main cohort entered the revaccination subcohort and received IM injection of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg (protein mixture) on Day 1095. Participants were then followed up for safety assessments till Day 1460.","deathsNumAffected":1,"deathsNumAtRisk":119,"seriousNumAffected":2,"seriousNumAtRisk":119,"otherNumAffected":84,"otherNumAtRisk":119}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Blood Loss Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Splenic Infarction","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Acute Coronary Syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Acute Left Ventricular Failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Acute Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Angina Unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Aortic Valve Disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Aortic Valve Stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Arteriosclerosis Coronary Artery","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":2891},{"groupId":"EG001","numAffected":3,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Atrial Flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":1,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cardiac Arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":3,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cardiac Failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cardiac Failure Congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":2891},{"groupId":"EG001","numAffected":3,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":1,"numAtRisk":119}]},{"term":"Cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Coronary Artery Disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":5,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":1,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Ischaemic Cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Left Ventricular Failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":2891},{"groupId":"EG001","numAffected":9,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":1,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Myocardial Ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Stress Cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":1,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Ventricular Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Inappropriate Antidiuretic Hormone Secretion","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Duodenal Ulcer Haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Food Poisoning","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Gastric Perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Gastrointestinal Haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hiatus Hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Inguinal Hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Intestinal Obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Intestinal Perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Large Intestinal Obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Obstructive Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Oesophageal Obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Oesophageal Perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pancreatic Cyst","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":1,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pancreatic Mass","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pancreatitis Acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Rectal Prolapse","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Small Intestinal Obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Upper Gastrointestinal Haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Adverse Drug Reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":1,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Chest Discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":3,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":2891},{"groupId":"EG001","numAffected":4,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Drowning","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Generalised Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Multiple Organ Dysfunction Syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Non-Cardiac Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":1,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cirrhosis Alcoholic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Abscess Neck","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Alpha Haemolytic Streptococcal Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":1,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Clostridium Difficile Colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":2891},{"groupId":"EG001","numAffected":13,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":1,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Covid-19 Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":2891},{"groupId":"EG001","numAffected":16,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Device Related Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Diabetic Foot Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Kidney Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Meningitis Aseptic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Periorbital Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":2891},{"groupId":"EG001","numAffected":10,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pneumonia Aspiration","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pneumonia Bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pneumonia Chlamydial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pneumonia Mycoplasmal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pneumonia Parainfluenzae Viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Septic Shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Streptococcal Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Ankle Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Carbon Monoxide Poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cervical Vertebral Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Craniocerebral Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Environmental Exposure","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Extradural Haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Facial Bones Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Femoral Neck Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Femur Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Fracture Displacement","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Head Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hip Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Humerus Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":1,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hypobarism","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Lumbar Vertebral Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Post Procedural Complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Road Traffic Accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Scapula Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Skin Abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Spinal Compression Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Spinal Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Subdural Haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Tibia Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Traumatic Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Upper Limb Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Wound Dehiscence","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":1,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Wrist Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Adult Failure to Thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Diabetes Mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Diabetic Ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Type 2 Diabetes Mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cervical Spinal Stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Chondrocalcinosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Intervertebral Disc Protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Kyphoscoliosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Musculoskeletal Chest Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":2891},{"groupId":"EG001","numAffected":6,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":1,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Rhabdomyolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Rotator Cuff Syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Spinal Stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":1,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Abdominal Neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Acute Myeloid Leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Adenocarcinoma of Colon","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Bladder Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Bladder Transitional Cell Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Brain Neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Breast Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":3,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cancer Pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Endometrial Adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hepatic Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hepatocellular Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Her2 Positive Breast Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Intraductal Proliferative Breast Lesion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Invasive Ductal Breast Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Lung Adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Lung Carcinoma Cell Type Unspecified Stage Iii","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Lung Carcinoma Cell Type Unspecified Stage Iv","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Lung Neoplasm Malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Marginal Zone Lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Metastases to Liver","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Metastatic Malignant Melanoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Metastatic Squamous Cell Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Non-Hodgkin's Lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Non-Small Cell Lung Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Oesophageal Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Ovarian Adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Ovarian Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pancreatic Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pancreatic Carcinoma Stage Iv","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Papillary Serous Endometrial Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Prostate Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":2891},{"groupId":"EG001","numAffected":4,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":1,"numAtRisk":119}]},{"term":"Prostate Cancer Metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Renal Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Renal Cell Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Small Cell Lung Cancer Extensive Stage","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Throat Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Transitional Cell Cancer of the Renal Pelvis and Ureter","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Transitional Cell Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Uterine Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Waldenstrom's Macroglobulinaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Autonomic Neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Carotid Artery Stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cerebral Haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cerebral Ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cerebrovascular Accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":1,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Intracranial Aneurysm","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Ischaemic Stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Lacunar Infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Lumbar Radiculopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":1,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Metabolic Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Myelopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Peroneal Nerve Palsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":3,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Subarachnoid Haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":1,"numAtRisk":119}]},{"term":"Toxic Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Transient Ischaemic Attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":4,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Trigeminal Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Alcoholism","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Bipolar Disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Depression Suicidal","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Major Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Mental Status Changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Acute Kidney Injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":1,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Chronic Kidney Disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":2,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Neurogenic Bladder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Renal Colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Renal Failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Renal Injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Ureterolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Benign Prostatic Hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Postmenopausal Haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Acute Respiratory Distress Syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Acute Respiratory Failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":2891},{"groupId":"EG001","numAffected":6,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Chronic Obstructive Pulmonary Disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":2891},{"groupId":"EG001","numAffected":4,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pleural Effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":1,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2891},{"groupId":"EG001","numAffected":5,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pulmonary Fibrosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pulmonary Haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pulmonary Oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Respiratory Failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Rotator Cuff Repair","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Aortic Aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Aortic Stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Arteriosclerosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Endothelial Dysfunction","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hypertensive Urgency","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Peripheral Arterial Occlusive Disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":0,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":1,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Peripheral Ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Vascular Compression","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2891},{"groupId":"EG001","numAffected":1,"numAtRisk":2891},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]}],"otherEvents":[{"term":"Iron Deficiency Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":1,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Angina Pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":2,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Aortic Valve Incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":1,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Atrial Flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Mitral Valve Incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Tricuspid Valve Incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":1,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":1,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":1,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Dental Caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":1,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":348},{"groupId":"EG001","numAffected":1,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":1,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":1,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":1,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Nausea (Solicited)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":348},{"groupId":"EG001","numAffected":7,"numAtRisk":347},{"groupId":"EG002","numAffected":4,"numAtRisk":120},{"groupId":"EG003","numAffected":5,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":3,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":10,"numAtRisk":137},{"groupId":"EG008","numAffected":22,"numAtRisk":149},{"groupId":"EG009","numAffected":3,"numAtRisk":37},{"groupId":"EG010","numAffected":1,"numAtRisk":37},{"groupId":"EG011","numAffected":4,"numAtRisk":37},{"groupId":"EG012","numAffected":9,"numAtRisk":131},{"groupId":"EG013","numAffected":12,"numAtRisk":119}]},{"term":"Plicated Tongue","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":1,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Fatigue (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":95,"numAtRisk":348},{"groupId":"EG001","numAffected":42,"numAtRisk":347},{"groupId":"EG002","numAffected":19,"numAtRisk":120},{"groupId":"EG003","numAffected":24,"numAtRisk":126},{"groupId":"EG004","numAffected":4,"numAtRisk":28},{"groupId":"EG005","numAffected":6,"numAtRisk":28},{"groupId":"EG006","numAffected":13,"numAtRisk":28},{"groupId":"EG007","numAffected":66,"numAtRisk":137},{"groupId":"EG008","numAffected":63,"numAtRisk":149},{"groupId":"EG009","numAffected":13,"numAtRisk":37},{"groupId":"EG010","numAffected":8,"numAtRisk":37},{"groupId":"EG011","numAffected":19,"numAtRisk":37},{"groupId":"EG012","numAffected":61,"numAtRisk":131},{"groupId":"EG013","numAffected":57,"numAtRisk":119}]},{"term":"Oedema Peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pyrexia (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":3,"numAtRisk":120},{"groupId":"EG003","numAffected":4,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":2,"numAtRisk":28},{"groupId":"EG007","numAffected":5,"numAtRisk":137},{"groupId":"EG008","numAffected":12,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":4,"numAtRisk":37},{"groupId":"EG012","numAffected":8,"numAtRisk":131},{"groupId":"EG013","numAffected":7,"numAtRisk":119}]},{"term":"Vaccination Site Erythema (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":348},{"groupId":"EG001","numAffected":7,"numAtRisk":347},{"groupId":"EG002","numAffected":8,"numAtRisk":120},{"groupId":"EG003","numAffected":4,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":4,"numAtRisk":28},{"groupId":"EG007","numAffected":11,"numAtRisk":137},{"groupId":"EG008","numAffected":6,"numAtRisk":149},{"groupId":"EG009","numAffected":1,"numAtRisk":37},{"groupId":"EG010","numAffected":2,"numAtRisk":37},{"groupId":"EG011","numAffected":4,"numAtRisk":37},{"groupId":"EG012","numAffected":18,"numAtRisk":131},{"groupId":"EG013","numAffected":7,"numAtRisk":119}]},{"term":"Vaccination Site Pain (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":120,"numAtRisk":348},{"groupId":"EG001","numAffected":24,"numAtRisk":347},{"groupId":"EG002","numAffected":37,"numAtRisk":120},{"groupId":"EG003","numAffected":29,"numAtRisk":126},{"groupId":"EG004","numAffected":9,"numAtRisk":28},{"groupId":"EG005","numAffected":11,"numAtRisk":28},{"groupId":"EG006","numAffected":18,"numAtRisk":28},{"groupId":"EG007","numAffected":93,"numAtRisk":137},{"groupId":"EG008","numAffected":81,"numAtRisk":149},{"groupId":"EG009","numAffected":26,"numAtRisk":37},{"groupId":"EG010","numAffected":16,"numAtRisk":37},{"groupId":"EG011","numAffected":29,"numAtRisk":37},{"groupId":"EG012","numAffected":91,"numAtRisk":131},{"groupId":"EG013","numAffected":64,"numAtRisk":119}]},{"term":"Vaccination Site Swelling (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":348},{"groupId":"EG001","numAffected":6,"numAtRisk":347},{"groupId":"EG002","numAffected":8,"numAtRisk":120},{"groupId":"EG003","numAffected":4,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":3,"numAtRisk":28},{"groupId":"EG007","numAffected":10,"numAtRisk":137},{"groupId":"EG008","numAffected":8,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":3,"numAtRisk":37},{"groupId":"EG011","numAffected":4,"numAtRisk":37},{"groupId":"EG012","numAffected":17,"numAtRisk":131},{"groupId":"EG013","numAffected":4,"numAtRisk":119}]},{"term":"Candida Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":1,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":1,"numAtRisk":37},{"groupId":"EG011","numAffected":1,"numAtRisk":37},{"groupId":"EG012","numAffected":2,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":1,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Oral Candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":1,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":348},{"groupId":"EG001","numAffected":14,"numAtRisk":347},{"groupId":"EG002","numAffected":3,"numAtRisk":120},{"groupId":"EG003","numAffected":2,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Tooth Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":1,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":348},{"groupId":"EG001","numAffected":10,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":1,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":348},{"groupId":"EG001","numAffected":4,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":1,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":1,"numAtRisk":119}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Thermal Burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":1,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Upper Limb Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":1,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Heart Rate Irregular","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":1,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":1,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":1,"numAtRisk":120},{"groupId":"EG003","numAffected":2,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":1,"numAtRisk":28},{"groupId":"EG007","numAffected":1,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":1,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Myalgia (Solicited)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":95,"numAtRisk":348},{"groupId":"EG001","numAffected":30,"numAtRisk":347},{"groupId":"EG002","numAffected":18,"numAtRisk":120},{"groupId":"EG003","numAffected":24,"numAtRisk":126},{"groupId":"EG004","numAffected":5,"numAtRisk":28},{"groupId":"EG005","numAffected":4,"numAtRisk":28},{"groupId":"EG006","numAffected":9,"numAtRisk":28},{"groupId":"EG007","numAffected":38,"numAtRisk":137},{"groupId":"EG008","numAffected":51,"numAtRisk":149},{"groupId":"EG009","numAffected":10,"numAtRisk":37},{"groupId":"EG010","numAffected":3,"numAtRisk":37},{"groupId":"EG011","numAffected":14,"numAtRisk":37},{"groupId":"EG012","numAffected":40,"numAtRisk":131},{"groupId":"EG013","numAffected":32,"numAtRisk":119}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":1,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":2,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Pain in Extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":1,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":1,"numAtRisk":119}]},{"term":"Basal Cell Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":1,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Diabetic Neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":348},{"groupId":"EG001","numAffected":5,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Headache (Solicited)","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":83,"numAtRisk":348},{"groupId":"EG001","numAffected":30,"numAtRisk":347},{"groupId":"EG002","numAffected":21,"numAtRisk":120},{"groupId":"EG003","numAffected":19,"numAtRisk":126},{"groupId":"EG004","numAffected":4,"numAtRisk":28},{"groupId":"EG005","numAffected":4,"numAtRisk":28},{"groupId":"EG006","numAffected":10,"numAtRisk":28},{"groupId":"EG007","numAffected":40,"numAtRisk":137},{"groupId":"EG008","numAffected":47,"numAtRisk":149},{"groupId":"EG009","numAffected":10,"numAtRisk":37},{"groupId":"EG010","numAffected":5,"numAtRisk":37},{"groupId":"EG011","numAffected":7,"numAtRisk":37},{"groupId":"EG012","numAffected":42,"numAtRisk":131},{"groupId":"EG013","numAffected":40,"numAtRisk":119}]},{"term":"Radicular Pain","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":1,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":1,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Nasal Polyps","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":1,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Sleep Apnoea Syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":1,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":1,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Tooth Extraction","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":0,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":0,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":1,"numAtRisk":37},{"groupId":"EG012","numAffected":0,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":348},{"groupId":"EG001","numAffected":0,"numAtRisk":347},{"groupId":"EG002","numAffected":0,"numAtRisk":120},{"groupId":"EG003","numAffected":0,"numAtRisk":126},{"groupId":"EG004","numAffected":0,"numAtRisk":28},{"groupId":"EG005","numAffected":3,"numAtRisk":28},{"groupId":"EG006","numAffected":0,"numAtRisk":28},{"groupId":"EG007","numAffected":0,"numAtRisk":137},{"groupId":"EG008","numAffected":1,"numAtRisk":149},{"groupId":"EG009","numAffected":0,"numAtRisk":37},{"groupId":"EG010","numAffected":0,"numAtRisk":37},{"groupId":"EG011","numAffected":0,"numAtRisk":37},{"groupId":"EG012","numAffected":1,"numAtRisk":131},{"groupId":"EG013","numAffected":0,"numAtRisk":119}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days."},"pointOfContact":{"title":"Medical Leader","organization":"Janssen Vaccines & Prevention B.V.","email":"ClinicalTrialDisclosure@its.jnj.com","phone":"844-434-4210"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-02-16","uploadDate":"2023-06-06T03:03","filename":"Prot_000.pdf","size":6215563},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-07-11","uploadDate":"2024-05-07T07:41","filename":"SAP_003.pdf","size":2025556}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Australia","Chile","New Zealand"],"submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-06-28","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D022261","term":"Respiratory Syncytial Virus Vaccines"}],"ancestors":[{"id":"D014765","term":"Viral Vaccines"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"}]}},"hasResults":true}